Do you want to read an article? Please log in or register.
Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults
Asthma
Related content
RECOMMENDED
Asthma
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
J Allergy Clin Immunol.
Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB
doi: 10.1016/j.jaci.2018.08.031.
Asthma
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Drug Des Devel Ther.
Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G
doi: 10.2147/
RECOMMENDED
Asthma
Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Prazma CM, Idzko M, Douglass JA, Bourdin A, Mallett S, Albers FC, Yancey SW
doi: 10.2147/JAA.S298559
RECOMMENDED
Asthma
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
J Allergy Clin Immunol.
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H
doi: 10.1016/j.jaci.2018.09.033.
RECOMMENDED
Further Publications
Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Wechsler ME, Peters SP, Hill TD, Ariely R, DePietro MR, Driessen MT, Terasawa EL, Thomason DR, Panettieri RA Jr
doi: 10.1016/j.chest.2020.11.060
Asthma
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Lancet Respir Med.
Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A
doi: 10.1016/
RECOMMENDED
Asthma
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Kayser MZ, Drick N, Milger K, Fuge J, Kneidinger N, Korn S, Buhl R, Behr J, Welte T, Suhling H
doi: 10.2147/JAA.S319572
Asthma
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
Drug Des Devel Ther.
Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G
doi: 10.2147/DDDT.S155307.
Asthma
Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma
Expert Opin Drug Metab Toxicol.
Matera MG, Calzetta L, Rinaldi B, Cazzola M
doi: 10.1080/17425255.